Shares of AVEO Pharmaceuticals (NASDAQ: AVEO) jumped 40% in August, according to data provided by S&P Global Market Intelligence as investors jump in ahead of data from its phase 3 Tivo-3 clinical trial, which is expected in the fourth quarter.
The Tivo-3 study is testing AVEO's tivozanib compared to Bayer's Nexavar as a third-line treatment for advanced renal cell carcinoma, a type of kidney cancer. The trial will be analyzed after the occurrence of 255 progression-free survival (PFS) events -- defined as the patient's tumor starting to grow or the patient dying.Shares fell in July after the company announced that the clinical trial results would be delayed, but the reason turned out to basically be a clerical error. At this point, the stock has regained all the ground it's lost, which seems about right.
AVEO has said that it plans to announce when the 255th event occurs and data will be released six to eight weeks after that since it takes some time to get all the data processed.
Even at this higher price, the market cap is under $500 million and investors can likely still profit from buying AVEO if the Tivo-3 results show tivozanib can increase PFS compared to Nexavar.
But an investment in AVEO is quite risky. With just $18.1 million in the bank at the end of the second quarter and the company having raised just $5.7 million last month, the Tivo-3 results are likely to be as binary as they come. If the clinical trial fails, it will be very hard for AVEO to recover.
10 stocks we like better than AVEO PharmaceuticalsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AVEO Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018